Perspectives on chemotherapy for the management of double-hit lymphoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. DOI:10.3322/caac.21551
   Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018. DOI:10.1038/s41591-018-0016-8.
   Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378:1396–1407.
   PubMed Web of Science ®Google Scholar
• Al Juhaishi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all? Expert Opin Pharmacother. 2019;20:773–775.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009;2009:523–531.
   Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. DOI:10.1182/blood-2016-01-643569
   PubMedGoogle Scholar
• Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37:3359–3368.
   Web of Science ®Google Scholar
• Leeman-Neill RJ, Bhagat G. BCL6 as a therapeutic target for lymphoma. Expert Opin Ther Targets. 2018;22:143–152.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Jiang A, Boyle M, et al. Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:190–201.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130:590–596.
   Web of Science ®Google Scholar
• Friedberg JW. How I treat double-hit lymphoma. Blood. 2017;130(5):590–596.
   Google Scholar
• Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604–616.
   PubMed Web of Science ®Google Scholar
• NCCN. Web site. B-cell lymphomas. [cited 2019 Oct 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.
   Google Scholar
• Reagan PM, Davies A. Current treatment of double hit and double expressor lymphoma. Hematology. 2017;2017(1):295–297.
   PubMedGoogle Scholar
• Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–2380.
   PubMed Web of Science ®Google Scholar
• Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496–502.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Geyer SM, Lozanski G, et al. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120:1677–1685.
   Web of Science ®Google Scholar
• Ok CY, Medeiros LJ. High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. Pathology. 2020 Jan;52(1):68-77. DOI:10.1016/j.pathol.2019.09.008. Epub 2019 Nov 15. Review. PubMed PMID: 31735344.
   Google Scholar
• Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319–2331.
   PubMed Web of Science ®Google Scholar
• Roth CG, Gillespie-Twardy A, Marks S, et al. Flow cytometric evaluation of double/triple hit lymphoma. Oncol Res. 2016;23:137–146.
   PubMed Web of Science ®Google Scholar
• Alsuwaidan A, Pirruccello E, Jaso J, et al. Bright CD38 expression by flow cytometric analysis is a biomarker for double/triple hit lymphomas with a moderate sensitivity and high specificity. Cytometry B Clin Cytom. 2019;96:368–374.
   Web of Science ®Google Scholar
• Rosenwald A, Sehn LH, Maucort-Boulch D. Prognostic significance of MYC single, double, triple hit and MYC-translocation partner status in diffuse large B-cell lymphoma - a study by the Lunenburg Lymphoma Biomarker Consortium (LLBC). Blood. 2018;132:344.
   Web of Science ®Google Scholar
• Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126:2466–2474.
   PubMed Web of Science ®Google Scholar
• Pedersen M, Gang AO, Poulsen TS, et al. MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol. 2014;92:42–48.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36:1603–1610.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis. Blood. 2014;124:2354–2361
   PubMedGoogle Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson cancer center clinical experience. Br J Haematol. 2014;166:891–901.
   PubMed Web of Science ®Google Scholar
• Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: A systematic review and meta-analysis. Br J Haematol. 2015;170:504–514.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609–e617.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Website. [cited 2019 Apr 11]. Available from: https://clinicaltrials.gov/ct2/home.
   Google Scholar
• Sun H, Savage KJ, Karsan A, et al. Outcome of patients with non-hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2015;15:341–348.
   Web of Science ®Google Scholar
• Zeng D, Desai A, Yan F, et al. Lymphoma With MYC and BCL2 and/or BCL6. Am J Clin Oncol. 2019;42(3):304–316.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150–3156.
   Google Scholar
• Cheah CY, Herbert KE, O’Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111:1072–1079.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Reddy N, Howlett C, et al. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. Blood. 2016;128:3455.
   PubMed Web of Science ®Google Scholar
• Othman J, Armytage T, Wong K, et al. Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma to the editor. Bone Marrow Transplant. 2020;5–8. DOI:10.1038/s41409-020-0789-5.
   Web of Science ®Google Scholar
• Tumati V, Trivedi L, Li HC, et al. Patterns of failure in patients with double hit or double expressor lymphomas: implications for radiation therapy. Int J Radiat Oncol Biol Phys. 2018;100:1126–1132.
   PubMed Web of Science ®Google Scholar
• Grass GD, Mills MN, Ahmed KA, et al. Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. Leuk Lymphoma. 2019;60:886–893.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Vardhana SA, Sauter CS, Matasar MJ, et al. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017;176:591–599.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Ayers EC, Bond DA, et al. Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. Br J Haematol. 2019. DOI:10.1111/bjh.16319.
   PubMed Web of Science ®Google Scholar
• Cuccuini W, Briere J, Mounier N, et al. MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012;119:4619–4624.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35:24–31.
   Web of Science ®Google Scholar
• Kritharis A, Coyle M, Sharma J, et al. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125:2471–2476.
   PubMed Web of Science ®Google Scholar
• Solomon LA, Batista CR, DeKoter RP. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB. Exp Hematol. 2017;56:46–57.e1.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Trněný M, Davies A, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-Cell lymphoma. Clin Cancer Res. 2017;23(15):4127LP- 4137.
   Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-hodgkin’s lymphoma. J Clin Oncol. 2008;26(30):4952–4957.
   PubMed Web of Science ®Google Scholar
• Chamuleau MED, Nijland M, Zijlstra JM, et al. Successful treatment of MYC rearrangement positive large B cell lymphoma patients with R-CHOP21 plus lenalidomide: results of a multicenter phase II HOVON trial. Blood. 2018;132(Suppl1):786LP–786.
   Google Scholar
• Chamuleau MED, Burggraaff CN, Nijland M, et al. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica. 2019. haematol.2019.238162. DOI:10.3324/haematol.2019.238162.
   Web of Science ®Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase i first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964 LP–1976.
   Web of Science ®Google Scholar
• Morschhauser F, Feugier P, Flinn IW, et al. Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line Diffuse Large B-Cell Lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI Study. Blood. 2018;132(Suppl1):782LP–782.
   Google Scholar
• Landsburg DJ, Hughes ME, Koike A, et al. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Adv. 2019;3(2):132LP–135.
   Web of Science ®Google Scholar
• Sethi A, Obi G, Manhas A, et al. Primary refractory double hit diffuse large B cell lymphoma: complete response with ibrutinib and rituximab. Clin Lymphoma Myeloma Leuk. 2018;18:S294.
   Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37:1285–1295.
   Web of Science ®Google Scholar
• Kharfan-dabaja MA, Ayala E, Kanate AS, et al. Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? Nat Publ Gr. 2017;52(11):1487–1494. .
   Google Scholar
• Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol. 2011;29:1855–1863.
   Google Scholar
• Van Besien KW, De Lima M, Giralt SA, et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997;19:977–982.
   Web of Science ®Google Scholar
• Bacher U, Klyuchnikov E, Carreras J, et al. Conditioning intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2011;118:501.
   Google Scholar
• Herrera AF, Rodig SJ, Song JY, et al. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. Biol Blood Marrow Transplant. 2018;24:514–520.
   Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
   Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36:7505.
   Web of Science ®Google Scholar
• Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267–270.
   Web of Science ®Google Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma. J Clin Oncol. 2019;37:3291–3299.
   Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed or refractory classical hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT): extended follow-up of the phase 2 single-arm checkmate 205 study. Blood. 2018;132:2897.
   Google Scholar
• Moskowitz CH, Zinzani PL, Fanale MA, et al. Pembrolizumab in relapsed/refractory classical hodgkin lymphoma: primary end point analysis of the phase 2 keynote-087 study. Blood. 2016;128:1107.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase IB study. J Clin Oncol. 2016;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Minnema MC, Johnson P, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019 January;JCO.18.00766. DOI:10.1200/JCO.18.00766.
   Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917.
   Google Scholar
• Li W, Gupta SK, Han W, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):1–13.
   PubMedGoogle Scholar
• Abramson JS, Blum KA, Flinn IW, et al. BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study. Blood. 2015;126(23):1491LP–1491.
   Web of Science ®Google Scholar
• Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in patients with relapsed or refractory non-hodgkin lymphoma. Blood. 2010;116(21):1777.
   Web of Science ®Google Scholar
• Deng C, Lipstein MR, Scotto L, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017;129(1):88–99.
   PubMed Web of Science ®Google Scholar
• Burris III HA, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018;19(4):486–496.
   PubMed Web of Science ®Google Scholar
• Hassan QN, Alinari L, Byrd JC. Plk1: A promising and previously unexplored target in double-hit lymphoma. J Clin Invest. 2018;128(12):5206–5208.
   PubMed Web of Science ®Google Scholar
• Ren Y, Bi C, Zhao X, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018;128(12):5531–5548.
   PubMed Web of Science ®Google Scholar